Colinz Labs

Which are the latest news on Colinz Labs?

Why is Colinz Laboratories Ltd falling/rising?

As of 05-Sep, Colinz Laboratories Ltd's stock price is rising at 72.56, with a 1.48% increase today and a year-to-date gain of 35.30%. However, concerns about weak long-term fundamentals and declining promoter confidence may affect future investor sentiment.

As of 05-Sep, Colinz Laboratories Ltd's stock price is rising, currently at 72.56, with a change of 1.06 (1.48%) increase. The stock has shown a positive performance today, outperforming its sector by 1.93% and has been on a consecutive gain for the last two days, accumulating a total return of 4.24% during this period. It opened with a gain of 2% today and reached an intraday high of Rs 73.65, reflecting strong market interest.<BR><BR>Despite some recent declines over the past week and month, where the stock fell by 1.95% and 6.97% respectively, its year-to-date performance is robust, with a 35.30% increase. Additionally, over the past year, the stock has generated a remarkable return of 69.57%, significantly outperforming the Sensex, which has seen a decline of 10.21% in the same timeframe.<BR><BR>However, it is important to note that while the stock is currently rising, there are underlying concerns regarding its long-term fundamentals. The company has shown weak growth in operating profits over the last five years and has a low return on equity of 5.18%. Furthermore, there has been a notable decrease in promoter confidence, with a 15.4% reduction in their stake, which may impact future investor sentiment. Despite these factors, the stock's recent performance and market dynamics have contributed to its current rise.

Who are in the management team of Colinz Labs?

The management team of Colinz Labs consists of L S Mani (Director & Company Secretary), N K Menon (Whole-time Director), Vasant K Bhat (Independent Director), and A Krishna Kumar (Independent Director).

The management team of Colinz Labs includes the following individuals:<BR><BR>1. L S Mani - Director & Company Secretary<BR>2. N K Menon - Whole-time Director<BR>3. Vasant K Bhat - Independent Director<BR>4. A Krishna Kumar - Independent Director<BR><BR>If you need more specific information about their roles or contributions, feel free to ask!

What does Colinz Labs do?

Colinz Laboratories Ltd is a micro-cap pharmaceutical and biotechnology company that manufactures and markets various pharmaceutical formulations. As of June 2026, it reported net sales of 1 Cr and a net profit of 2 Cr, with a market cap of INR 19 Cr.

Overview:<BR>Colinz Laboratories Ltd is a pharmaceutical and biotechnology company operating in the micro-cap market, specializing in the manufacturing and marketing of a wide variety of pharmaceutical formulations.<BR><BR>History:<BR>Colinz Laboratories Ltd was incorporated as a Private Limited Company in 1986 and converted into a Public Limited Company in 1995, the same year it began its manufacturing and marketing activities. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 2 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 19 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 37.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.81 <BR>Return on Equity: 5.04% <BR>Price to Book: 1.86 <BR><BR>Contact Details:<BR>Address: A-101 Pratik Industrial Estate, Mulund Goregaon Link Road Mumbai Maharashtra : 400078 <BR>Tel: 91-022-25668002/8003 <BR>Email: colinzlabs@yahoo.com <BR>Website: http://www.cindoc-cll.in

Who are the peers of the Colinz Labs?

Colinz Labs' peers include Welcure Drugs, Venmax Drugs, Ishita Drugs, and others, with varying management and growth risks. Colinz Labs leads with an 80.21% one-year return, significantly outperforming its peers.

Peers: The peers of Colinz Labs are Welcure Drugs, Venmax Drugs, Ishita Drugs, Shree Ganesh Bio, Centuple Global, Bacil Pharma, Zenith Health, Desh Rakshak, Saroja Pharma In.<BR><BR>Quality Snapshot: Excellent management risk is observed at Centuple Global, while Average management risk is found at Welcure Drugs, Saroja Pharma In, and the rest. Below Average management risk is noted at Venmax Drugs, Ishita Drugs, Shree Ganesh Bio, Colinz Labs, Zenith Health, and Desh Rakshak. For Growth, Good growth is seen at Centuple Global and Ishita Drugs, while Below Average growth is present at Welcure Drugs, Venmax Drugs, Shree Ganesh Bio, Colinz Labs, Zenith Health, Desh Rakshak, and the rest. Good capital structure is noted at Welcure Drugs, Ishita Drugs, Shree Ganesh Bio, Colinz Labs, and Zenith Health, while Below Average capital structure is found at Venmax Drugs, Desh Rakshak, and the rest.<BR><BR>Return Snapshot: Colinz Labs has the highest 1-year return at 80.21%, while Welcure Drugs has the lowest at -72.73%. Colinz Labs' return significantly outperforms its peers. Additionally, Bacil Pharma, Desh Rakshak, and Saroja Pharma In have negative six-month returns.

How big is Colinz Labs?

As of 31st August, Colinz Laboratories Ltd has a market capitalization of 19.00 Cr, with recent net sales of 5.81 Cr and a net profit of 2.79 Cr. The balance sheet for March 2026 shows shareholder's funds of 10.04 Cr and total assets of 12.78 Cr.

As of 31st August, Colinz Laboratories Ltd has a market capitalization of 19.00 Cr, which categorizes it as a Micro Cap company.<BR><BR>In the latest four quarters, Colinz Laboratories Ltd reported Net Sales of 5.81 Cr and a Net Profit of 2.79 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, showing Shareholder's Funds of 10.04 Cr and Total Assets of 12.78 Cr.

Are Colinz Laboratories Ltd latest results good or bad?

Colinz Laboratories Ltd's latest results show a significant net profit increase of 1,311.76% to ₹2.40 crores, but this is largely due to extraordinary items rather than strong operational performance. Revenue fell 29.14% to ₹1.24 crores, raising concerns about sustainability and indicating underlying challenges, so investors should proceed with caution.

Colinz Laboratories Ltd's latest results present a mixed picture. On one hand, the company reported a significant net profit of ₹2.40 crores for Q1 FY27, which reflects an impressive increase of 1,311.76% quarter-on-quarter. However, this surge in profit appears to be driven by extraordinary items rather than strong operational performance.<BR><BR>In contrast, the company's revenue for the same quarter fell sharply to ₹1.24 crores, marking a decline of 29.14% from the previous quarter. This revenue contraction is concerning, especially as it also represents a year-on-year decrease of 21.02%. The operating profit margin has also decreased slightly to 4.84%, indicating challenges in maintaining profitability from core operations.<BR><BR>Furthermore, the substantial profit before tax figure of ₹2.90 crores raises questions about the sustainability of these earnings, as it seems disconnected from the lower revenue figures. The operational metrics suggest that the company is facing significant challenges, including a negative five-year sales growth and a notable reduction in promoter holding, which could indicate a lack of confidence in the company's future prospects.<BR><BR>Overall, while the headline profit figure looks good, the underlying operational difficulties and declining revenue suggest that the results are not as positive as they might initially seem. Investors should approach with caution and seek clarity on the nature of the profit surge before making any decisions.

Should I buy, sell or hold Colinz Laboratories Ltd?

When is the next results date for Colinz Laboratories Ltd?

The next results date for Colinz Laboratories Ltd is 30 July 2026.

The next results date for Colinz Laboratories Ltd is scheduled for 30 July 2026.

Is Colinz Labs overvalued or undervalued?

As of November 3, 2025, Colinz Labs is overvalued with a PE ratio of 42.76 and a year-to-date decline of 35.64%, indicating a concerning long-term outlook despite a recent short-term gain.

As of 3 November 2025, Colinz Labs has moved from a fair to an expensive valuation grade. The company is currently overvalued, with a PE ratio of 42.76, an EV to EBIT of 15.61, and a ROE of 5.07%. In comparison to its peers, Sun Pharma has a PE of 35.62 and an EV to EBITDA of 24.18, while Cipla shows a more attractive PE of 22.44 and an EV to EBITDA of 5.66, highlighting Colinz Labs' relatively high valuation metrics.<BR><BR>Despite a recent uptick in stock price, with a 1-week return of 3.46% compared to a -0.94% return on the Sensex, the overall performance year-to-date shows a decline of 35.64% against a 7.47% increase in the Sensex. This suggests that while there may be short-term gains, the long-term outlook for Colinz Labs remains concerning given its current overvaluation in the context of its peers.

How has been the historical performance of Colinz Labs?

Colinz Labs has experienced a downward trend in net sales, reporting 6.53 Cr in March 2025, down from 7.03 Cr in March 2024. Despite a slight increase in profit after tax to 0.50 Cr, negative cash flow and declining revenues raise concerns about its financial stability.

Answer:<BR>The historical performance of Colinz Labs shows a fluctuating trend in net sales and profits over the years, with a slight decline in recent periods.<BR><BR>Breakdown:<BR>Colinz Labs reported net sales of 6.53 Cr in March 2025, down from 7.03 Cr in March 2024 and 7.15 Cr in March 2023, indicating a downward trend in revenue. The total operating income mirrored this decline, remaining at 6.53 Cr in March 2025. The company's total expenditure, excluding depreciation, decreased to 6.03 Cr in March 2025 from 6.49 Cr in March 2024. Operating profit (PBDIT) was 0.80 Cr in March 2025, slightly lower than 0.82 Cr in March 2024, while profit before tax was 0.62 Cr, down from 0.65 Cr the previous year. Profit after tax showed a modest increase to 0.50 Cr in March 2025 from 0.49 Cr in March 2024. The company's total assets rose to 11.82 Cr in March 2025 from 11.36 Cr in March 2024, and total liabilities also increased to 11.82 Cr from 11.36 Cr. Cash flow from operating activities turned negative at -1.00 Cr in March 2025, contrasting with a positive inflow of 1.00 Cr in March 2024. Overall, while Colinz Labs has shown some resilience in profit margins, the decline in sales and cash flow raises concerns about its financial stability.

Who are the top shareholders of the Colinz Labs?

The top shareholder of Colinz Labs is Mani L S, holding 34.45% of the shares, with no pledged promoter holdings. The highest public shareholder is Dipakbhai Haribhai Gaudani at 1.31%, while individual investors collectively own 31.04%.

The top shareholders of Colinz Labs include the promoters, with Mani L S holding the largest share at 34.45%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Dipakbhai Haribhai Gaudani, who holds 1.31%. Additionally, individual investors collectively hold 31.04% of the shares.

What is the technical trend for Colinz Labs?

As of 26 May 2025, Colinz Labs shows a bullish technical trend supported by positive daily and weekly indicators, although caution is advised due to mildly bearish signals from the monthly MACD and Dow Theory.

As of 26 May 2025, the technical trend for Colinz Labs has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the upward momentum, while the daily moving averages also indicate a bullish stance. The KST is bullish on both weekly and monthly time frames, reinforcing the positive outlook. However, the monthly MACD and Dow Theory show mildly bearish signals, suggesting some caution. Overall, the current technical stance is bullish with moderate strength, driven primarily by the bullish indicators on the daily and weekly charts.

Has Colinz Labs declared dividend?

No Dividend History Available